Verve Therapeutics, Inc.
Verve Therapeutics, Inc.
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Not yet recruiting | Phase 2 | 2026-09-24 | NCT07839936 | |
| A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease | Arterial Occlusive Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, familial hypercholesterolemia, heart disorder, hereditary disease, hyperlipidemia, hyperlipoproteinemia, inborn errors of metabolism, metabolic disease, myocardial ischemia, vascular disorder | Recruiting | Phase 1 | 2026-09-02 | NCT06164730 | |
| Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, familial hypercholesterolemia, hereditary disease, hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, inborn errors of metabolism, metabolic disease | Recruiting | Phase 1 | 2026-07-17 | NCT06451770 | |
| Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease | Arterial Occlusive Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, familial hypercholesterolemia, hereditary disease, hyperlipidemia, hyperlipoproteinemia, inborn errors of metabolism, metabolic disease, vascular disorder | Enrolling by invitation | Not stated | 2026-04-08 | NCT06112327 |